The company has managed to show leadership by creating dedicated investment to appropriately balance environmental targets and long-term sustainable business growth coupled with digital adoption to enhance operations
Earlier, the USFDA has granted ‘Orphan Drug Designation’ and ‘Fast Track Designation’ to Saroglitazar Mg for PBC
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
The plant will become operational by late 2023 and this investment is planned as the first of three phase investment
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
Oil price rise made profit from their inventory, letting them to make profits continuously in oil refinery industry
With this tie-up, Fineotex will add to its portfolio the much-required metal-free safety for its customers around the world with all the required global certifications
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
Company reported net sales of $4.4 billion, approximately 45% higher than the prior year, Selling prices increased by 3.5% and sales volumes were higher by approximately 24% in comparison to the previous year
Trinseo anticipates the transaction will close by year-end 2021 subject to customary closing conditions and regulatory approvals
The increase will result from the relocation of its production site from Suzhou to Ningbo, China, which is scheduled to be completed by the end of 2021
As of 2025, the new Translational Science Center will offer room for more than 500 scientists, who will conduct research in a wide variety of fields ranging from the identification of disease biomarkers to the development of targeted therapies
The business provides flavors and flavor technologies to the food, beverage, and nutraceutical markets
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Second-quarter net income was USD 539 million (USD 2.10 per share) compared with USD 223 million (USD 0.83 per share) a year earlier
The objective of the purchase of the shares of RPCPPL is to consolidate the shareholding of the company in RPCPPL.
As per the agreement and subject to customary closing conditions, Rossari will be acquiring 100% of the equity share capital of Tristar Intermediates
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
MCC is developing multiple new carbon fiber-related products that can meet the diversified and sophisticated needs of our customers.
The company has consistently invested in R&D capabilities and technologies
Subscribe to our newsletter & stay updated.
